Intuitive Surgical, Inc. vs NeoGenomics Inc. Common Stock — how do they compare? Intuitive Surgical, Inc. trades at $422.44 (market cap $148.46B), while NeoGenomics Inc. Common Stock trades at $17.17 (market cap $2.17B). The key difference: Intuitive Surgical, Inc. is far larger — about 68.4× NeoGenomics Inc. Common Stock's market cap, and NeoGenomics Inc. Common Stock is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| ISRG | NEO | |
|---|---|---|
Market Cap | $148.46B | $2.17B |
Volume | 1,914,576 | 1,615,943 |
Sector | Health | Health |
52-Week High | $592.85 | $19.91 |
52-Week Low | $332.02 | $7.19 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $143.25B | $2.47B |
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $422.06, down 1.3% on the day, but maintains strong fundamentals with consistent earnings beats and robust revenue growth from $6.2B in 2022 to $10.1B in 2025. The stock shows bullish technical signals with support at $414 and resistance at $431, while analyst consensus remains strongly positive with a $480.78 price target. Recent expansion into India and Japan helps offset China weakness, with da Vinci 5 upgrades driving recurring revenue streams.
ISRG presents a compelling growth opportunity with market leadership in robotic surgery and expanding international presence, though elevated valuation multiples (P/E 48.4) and competitive pressures warrant caution. The 70% buy rating from analysts suggests significant upside potential, but investors should monitor procedure growth rates and macroeconomic pressures affecting healthcare spending.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →